1. Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial. (11th June 2018) Authors: Ignatiadis, M; Litière, S; Rothe, F; Riethdorf, S; Proudhon, C; Fehm, T; Aalders, K; Forstbauer, H; Fasching, P A; Brain, E; Vuylsteke, P; Guardiola, E; Lorenz, R; Pantel, K; Tryfonidis, K; Janni, W; Piccart, M; Sotiriou, C; Rack, B; Pierga, J -Y Journal: Annals of oncology Issue: Volume 29:Number 8(2018) Page Start: 1777 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis. (22nd January 2018) Authors: Bareche, Y; Venet, D; Ignatiadis, M; Aftimos, P; Piccart, M; Rothe, F; Sotiriou, C Journal: Annals of oncology Issue: Volume 29:Number 4(2018) Page Start: 895 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗